Sea Mild Biotechnology Co., Ltd.

TPEX:7516 Rapporto sulle azioni

Cap. di mercato: NT$173.4m

Sea Mild Biotechnology Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Sea Mild Biotechnology has a total shareholder equity of NT$86.2M and total debt of NT$53.3M, which brings its debt-to-equity ratio to 61.9%. Its total assets and total liabilities are NT$243.6M and NT$157.4M respectively. Sea Mild Biotechnology's EBIT is NT$11.5M making its interest coverage ratio 14.3. It has cash and short-term investments of NT$63.4M.

Informazioni chiave

61.9%

Rapporto debito/patrimonio netto

NT$53.33m

Debito

Indice di copertura degli interessi14.3x
ContantiNT$63.42m
Patrimonio nettoNT$86.21m
Totale passivitàNT$157.39m
Totale attivitàNT$243.59m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: 7516's short term assets (NT$195.9M) exceed its short term liabilities (NT$155.0M).

Passività a lungo termine: 7516's short term assets (NT$195.9M) exceed its long term liabilities (NT$2.4M).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 7516 has more cash than its total debt.

Riduzione del debito: 7516's debt to equity ratio has increased from 1.9% to 61.9% over the past 5 years.

Copertura del debito: 7516's operating cash flow is negative, therefore debt is not well covered.

Copertura degli interessi: 7516's interest payments on its debt are well covered by EBIT (14.3x coverage).


Bilancio


Scoprire le aziende sane